Trials / Completed
CompletedNCT02144272
Safety Study to Evaluate LY3114062 in Participants With Inflammatory Arthritis
A Phase 1 Single-Dose, Dose Escalation Study to Evaluate the Safety and Tolerability of LY3114062 in Subjects With Inflammatory Arthritis
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to learn more about the safety of LY3114062 and to find out how well it is tolerated in participants with an inflammatory arthritis. The study will also investigate how the body processes the drug and how the drug affects inflammatory arthritis. The study is expected to last about 3 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3114062 SC | LY3114062 administered SC. |
| DRUG | Placebo | Placebo administered SC. |
| DRUG | LY3114062 IV | LY3114062 administered IV. |
Timeline
- Start date
- 2014-06-01
- Primary completion
- 2015-05-01
- Completion
- 2015-06-01
- First posted
- 2014-05-21
- Last updated
- 2015-07-17
Locations
4 sites across 4 countries: Bulgaria, Georgia, Moldova, Romania
Source: ClinicalTrials.gov record NCT02144272. Inclusion in this directory is not an endorsement.